Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The current ratio is N/A as of Tuesday, October 6, 2026.
CURRENT RATIO
N/A
Market Cap
$848.19M
Current Ratio
9.52
TTM Avg
4.26
3Y Avg
6.09
5Y Avg
7.80
Market Cap
$852.65M
Current Ratio
14.93
TTM Avg
20.63
3Y Avg
16.30
5Y Avg
22.70
Market Cap
$804.39M
Current Ratio
4.26
TTM Avg
4.46
3Y Avg
3.96
5Y Avg
4.08
Market Cap
$884.63M
Current Ratio
16.16
TTM Avg
3.88
3Y Avg
3.97
5Y Avg
4.50
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $851.42M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $848.19M | 9.52 | 4.26 | 6.09 | 7.80 |
| Jade Biosciences, Inc. (JBIO)vs › | $852.65M | 14.93 | 20.63 | 16.30 | 22.70 |
| Beta Bionics, Inc. (BBNX)vs › | $857.50M | 8.88 | 7.47 | 6.98 | 6.98 |
| Alumis Inc. (ALMS)vs › | $830.08M | 6.74 | 5.17 | 5.15 | 5.15 |
| Ardelyx, Inc. (ARDX)vs › | $823.84M | 3.34 | 4.45 | 4.03 | 4.25 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $804.39M | 4.26 | 4.46 | 3.96 | 4.08 |
| InMode Ltd. (INMD)vs › | $813.07M | 8.18 | 10.05 | 10.24 | 9.72 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $884.63M | 16.16 | 3.88 | 3.97 | 4.50 |
| Arbutus Biopharma Corp (ABUS)vs › | $896.17M | 81.42 | 11.94 | 8.59 | 10.34 |
Current Ratio
N/A
Quick Ratio
N/A
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
